Skip to content
value.today

Kindred Biosciences, Inc.

Total raised
$12 M
3 rounds on record
Latest round
$5 M
Aug 2013
First round on record
Nov 2012
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kindred Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2013$5 MNo. 3$2 to $10 million

Kindred Biosciences, Inc.: Raise no. 3, Aug 2013

Investors in this round

18 investors had bought by the notice of Sep 20, 2013: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$78,000
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Denise Bevers · Executive Officer
  • Richard Chin · Executive Officer, Director
  • Stephen Sundlof · Executive Officer
  • Ernest Mario · Director
  • Ervin Vezspremi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • SDDCO Brokerage Advisors (CRD 153563) · New York, New YorkSold in CA, NY

Signed by Richard Chin, Ceo. Source: SEC Form D, newest notice filed Sep 20, 2013. Read the notice at the SEC.

equitySEC
Jun 2013$6 MNo. 2$2 to $10 million

Kindred Biosciences, Inc.: Raise no. 2, Jun 2013

Investors in this round

50 investors had bought by the notice of Sep 13, 2013: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Denise Bevers · Executive Officer
  • Richard Chin · Executive Officer, Director
  • Stephen Sundlof · Executive Officer
  • Ernest Mario · Director
  • Ervin Vezspremi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard Chin, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Sep 13, 2013. Read the notice at the SEC.

equitySEC
Nov 2012$1 MNo. 1Under $2 million

Kindred Biosciences, Inc.: Raise no. 1, Nov 2012

Investors in this round

16 investors had bought by the notice of Nov 19, 2012: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$5,000
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard Chin · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard Chin, President & CEO. Source: SEC Form D, newest notice filed Nov 19, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kindred Biosciences, Inc. had no revenue when it filed its newest notice of a funding round (Sep 2013).

    SEC Form D (revenue range) · Sep 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2013

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Kindred Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 50 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kindred Biosciences, Inc.
NameRoleNamed in
Denise BeversExecutive officerSep 2013
Richard ChinExecutive officerSep 2013
Stephen SundlofExecutive officerSep 2013
Ernest MarioDirectorSep 2013
Ervin VezspremiDirectorSep 2013
Richard ChinDirectorSep 2013